middle.news
Alterity Therapeutics Secures A$40M to Accelerate ATH434 Parkinsonian Drug Trials
9:12am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Alterity Therapeutics Secures A$40M to Accelerate ATH434 Parkinsonian Drug Trials
9:12am on Monday 2nd of June, 2025 AEST
Key Points
A$40 million capital raise via two-tranche placement
Funds primarily to advance ATH434 clinical development in Parkinsonian disorders
Strong institutional investor support domestically and internationally
Positive Phase 2 ATH434 data showing 48% slowing of MSA progression
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE